HF-158K1 by HighField Biopharmaceuticals for Cervical Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Cervical Cancer.

Congress: Close Medicare’s dangerous gaps in coverage for addiction treatment

While many people immediately picture young adults when thinking about the current addiction and overdose epidemic, this crisis is affecting all generations. In fact, more

May 13, 2024

NIH supports research on non-opioid pain relief for oral cancer patients

The School of Dentistry at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) earned the first National Institutes of

October 4, 2024

SPY stock analysis & what to watch for beyond the Federal Reserve meeting for SPY stock

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.